|
1.
|
Cho J and Mosher DF: Enhancement of
thrombogenesis by plasma fibronectin cross-linked to fibrin and
assembled in platelet thrombi. Blood. 107:3555–3563. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bennett JS: Structure and function of the
platelet integrin alpha-Ibbeta3. J Clin Invest. 115:3363–3369.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Davì G and Patrono C: Platelet activation
and atherothrombosis. N Engl J Med. 357:2482–2494. 2007.
|
|
4.
|
Bode C, Runge MS, Schönermark S, et al:
Conjugation to antifibrin Fab’ enhances fibrinolytic potency of
single-chain urokinase plasminogen activator. Circulation.
81:1974–1980. 1990.PubMed/NCBI
|
|
5.
|
Peterson E, Owens SM and Henry RL:
Monoclonal antibody form and function: manufacturing the right
antibodies for treating drug abuse. AAPS J. 8:E383–E390.
2006.PubMed/NCBI
|
|
6.
|
Xia HL, Tan Z, Chen DJ, Qiao JG and Qiu
RF: Isolation of specific humanized anti-D-dimer scFv fragments
from scFv phage libraries. Zhonghua Wei Sheng Wu Xue He Mian Yi Xue
Za Zhi. 31:168–172. 2011.(In Chinese).
|
|
7.
|
Xia HL, Tan Z, Chen DJ, Qiao JG and Qiu
RF: Production of monoclonal anti-GP II b/IIIa scFv antibodies from
scFv phage libraries. Chin J Exp Surg. 28:529–532. 2011.
|
|
8.
|
Dincq S, Bosman F, Buyse MA, et al:
Expression and purification of monospecific and bispecific
recombinant antibody fragments derived from antibodies that block
the CD80/CD86-CD28 costimulatory pathway. Protein Expr Purif.
22:11–24. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Jongmans W, van den Oudenalder K,
Tiemessen DM, et al: Targeting of adenovirus to human renal cell
carcinoma cells. Urology. 62:559–565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Holvoet P, Laroche Y, Stassen JM, et al:
Pharmacokinetic and thrombolytic properties of chimeric plasminogen
activators consisting of a single-chain Fv fragment of a
fibrin-specific antibody fused to single-chain urokinase. Blood.
81:696–703. 1993.
|
|
11.
|
Dewerchin M, Vandamme AM, Holvoet P, et
al: Thrombolytic and pharmacokinetic properties of a recombinant
chimeric plasminogen activator consisting of a fibrin fragment
D-dimer specific humanized monoclonal antibody and a truncated
single-chain urokinase. Thromb Haemost. 68:170–179. 1992.
|
|
12.
|
Peter K, Graeber J, Kipriyanov S, et al:
Construction and functional evaluation of a single-chain antibody
fusion protein with fibrin targeting and thrombin inhibition after
activation by factor Xa. Circulation. 101:1158–1164. 2000.
View Article : Google Scholar
|
|
13.
|
Okabayashi K, Tsujikawa M, Morita M, et
al: Secretory production of recombinant urokinase-type plasminogen
activator-annexin V chimeras in Pichia pastoris. Gene.
177:69–76. 1996. View Article : Google Scholar
|
|
14.
|
Jiang P, Changgeng R and Ru B:
Construction and expression of antibody targeted plasminogen
activator*. Enzyme Microb Technol. 27:755–760. 2000.
|
|
15.
|
Stoll P, Bassler N, Hagemeyer CE, et al:
Targeting ligand-induced binding sites on GPIIb/IIIa via
single-chain antibody allows effective anticoagulation without
bleeding time prolongation. Arterioscler Thromb Vasc Biol.
27:1206–1212. 2007. View Article : Google Scholar
|
|
16.
|
Ruef J, Nordt TK, Peter K, Runge MS,
Kübler W and Bode C: A bispecific antifibrin-antiplatelet urokinase
conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet
aggregation. Thromb Haemost. 82:109–114. 1999.
|
|
17.
|
Tcheng JE, Kereiakes DJ, Lincoff AM, et
al: Abciximab read-ministration: results of the ReoPro
Readministration Registry. Circulation. 104:870–875. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Leath CA III, Douglas JT, Curiel DT and
Alvarez RD: Single-chain antibodies: A therapeutic modality for
cancer gene therapy (review). Int J Oncol. 24:765–771.
2004.PubMed/NCBI
|
|
19.
|
Holliger P, Prospero T and Winter G:
“Diabodies”: small bivalent and bispecific antibody fragments. Proc
Natl Acad Sci USA. 90:6444–6448. 1993.
|
|
20.
|
Liu F, Chen Z, Jiang W, Yang C, Xiong D
and Zhu Z: Improvement in soluble expression levels of a diabody by
exchanging expression vectors. Protein Expr Purif. 62:15–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Stamova S, Cartellieri M, Feldmann A, et
al: Unexpected recombinations in single chain bispecific
anti-CD3-anti-CD33 antibodies can be avoided by a novel linker
module. Mol Immunol. 49:474–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kriangkum J, Xu B, Nagata LP, Fulton RE
and Suresh MR: Bispecific and bifunctional single chain recombinant
antibodies. Biomol Eng. 18:31–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
